Saterex is the first Russian original DPP-IV inhibitor (gosogliptin) for the treatment of type 2 diabetes mellitus that provides a timely and safe treatment with a domestically manufactured drug. Gosogliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-IV) inhibitor for the treatment of type 2 diabetes mellitus. Inhibiting DPP-IV, gosogliptin increases concentrations of Incretin hormones secreted in the intestine: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). An increase in GLP-1 and GIP concentrations results in an enhanced sensitivity of pancreatic beta-cells to blood glucose which leads in an increase in the synthesis and release of insulin. An increase in GLP-1 levels also enhances sensitivity of pancreatic alpha-cells to glucose which results in an improved glucose-dependent regulation of glucagon secretion. A decrease of the increased glucagon secretion during a meal results in a decreased insulin resistance. Decreased glucagon levels together with increased insulin levels due to the increased GLP-1 and GIP concentrations results in a reduced production of glucose by the liver which leads to a lower blood glucose concentrations. In patients with type 2 diabetes mellitus, these changes in the insulin secretion result in reducing concentrations of glycosylated hemoglobin (HbA1c) and of both fasted and postprandial blood glucose.